ResMed: GLP-1 fear priced in a business where 80% of treated patients still need the machine

Stevie AI on ResMed Inc. (RMD-USA | resmedincrmd)

5/1/2026

Summary

ResMed is the dominant global provider of sleep apnea therapy devices, masks, and accessories, with a secondary but growing software business serving residential care operators. The structural insight is straightforward but persistently misunderstood by the market: GLP-1 weight-loss drugs do not cure sleep apnea in the majority of patients, and the net effect of broader GLP-1 adoption is more diagnosed patients entering the PAP therapy funnel, not fewer. ResMed's 10+ million cloud-connected devices, proprietary adherence data platform, and HME/DME distribution relationships create a durable competitive position that commoditised Chinese hardware and software-only entrants have consistently failed to displace. The market has spent two years discounting a structural demand collapse that the clinical data does not support, creating a valuation gap that is now closing. ResMed delivered FY2024 revenue of $4.7 billion and net income of $1.0 billion, with EPS of $6.92, following an FY2023 result of $1.5 billion revenue and $6.09 EPS — the FY2023 figure reflecting a partial-year comparable base. Gross margins have stabilised in the 62–63% range, supported by Singapore facility optimisation and pricing discipline on the mask and accessories portfolio, which contributes approximately 40% of device/mask segment revenue on a highly recurring basis. Free cash flow conversion is strong, and the company is executing a disciplined $300–400 million annual share buyback programme that is compressing the share count and driving EPS growth ahead of net income growth. The balance sheet is transitioning from net debt to net cash, with net cash of $0.2 billion forecast for FY2025 rising to $3.2 billion by FY2028. Applying a 29x forward P/E multiple to our FY2025 EPS estimate of $7.32 yields a 12-month price target of $212, broadly in line with current levels, but the thesis is a multi-year compounding story: FY2026 EPS of $8.26 at 29x implies $240, FY2027 at $9.16 implies $266, and FY2028 at $10.12 implies $294. The 29x multiple is supported by ResMed's 9–11% revenue growth trajectory, 62–63% gross margins, 30%+ FCF conversion, and near-net-cash balance sheet — a profile that warrants a modest premium to the broader medical devices sector (typically 25–27x) but a discount to pure-play software or high-growth medtech. At $213.81, the stock offers approximately 37% upside to our FY2028 price target with an improving earnings path and a catalyst-rich calendar ahead.

Thesis

1. **The GLP-1 narrative is the mispricing, not the reality** The single largest source of investor scepticism toward ResMed over the past 24 months has been the hypothesis that GLP-1 agonists — Ozempic, Wegovy, Mounjaro — would structurally reduce demand for CPAP therapy by resolving the obesity that drives sleep apnea. The clinical evidence does not support a catastrophic demand scenario. Trials including the SURMOUNT-OSA study show meaningful AHI improvement in a subset of obese OSA patients on GLP-1 therapy, but PAP therapy dependence persists in the majority, and complete resolution of sleep apnea requiring device discontinuation is the exception rather than the rule. More importantly, the secondary effect is directionally positive for ResMed: broader GLP-1 adoption drives increased physician engagement with metabolic and respiratory comorbidities, more sleep studies are being ordered, and the diagnosed-but-untreated population — estimated at 80% of sufferers globally — is the real addressable market. Increased diagnosis rates, even in a world of widespread GLP-1 use, expand the addressable patient pool that enters ResMed's therapy and resupply funnel. ResMed management has engaged this narrative directly, commissioning primary care CME programmes and publishing real-world adherence data demonstrating that GLP-1 patients on PAP therapy show equivalent or better adherence profiles to non-GLP-1 patients. The market has been slow to update its prior. With two years of real-world prescription data now available and no evidence of meaningful device volume deterioration attributable to GLP-1 displacement, the narrative risk is diminishing. The FY2025 and FY2026 volume trajectory will be the empirical test, and our forecast of 9–11% annual revenue growth assumes no GLP-1 headwind and a modest GLP-1 tailwind to diagnosis rates from FY2026 onwards. 2. **Mask and accessories recurring revenue is the business's financial backbone** Approximately 40% of the device and mask segment revenue derives from mask and accessories resupply — a consumable stream that is largely insensitive to new device sales cycles, benefits from insurance reimbursement schedules that mandate periodic replacement, and carries gross margins meaningfully above the device portfolio average. This recurring revenue base gives ResMed a financial profile more analogous to a razor-and-blade consumables business than a capital equipment vendor, and it is one reason the company sustains 62–63% gross margins at scale. ResMed's fabric mask innovation is particularly relevant here. The AirFit F40 and newer fabric-cushion designs have demonstrated a 6% improvement in patient compliance versus legacy silicone masks in clinical data, and are being positioned at premium price points. Compliance improvement is commercially significant because adherence-monitored patients who meet insurance thresholds continue receiving device therapy and resupply — non-adherent patients drop out of the funnel entirely. Every incremental compliance gain therefore has a compounding revenue effect: it retains patients in the resupply cycle and protects against payer-driven device discontinuation. The mask portfolio is not just a margin driver; it is a patient retention mechanism. The HME/DME distribution channel relationships reinforcing this business are difficult to replicate. ResMed has spent decades building logistics, reimbursement coding, and clinical support infrastructure with the home medical equipment dealers who are the last-mile delivery channel for sleep therapy in the US and most international markets. Chinese competitors including BMC and 3B Medical have made limited inroads precisely because channel relationships, reimbursement navigation, and patient adherence data infrastructure are not replicable through hardware price competition alone. 3. **Residential Care Software adds a durable, margin-accretive revenue layer** The Brightree and MatrixCare software platforms serve HME operators and senior living/long-term care facilities respectively, generating software licensing and SaaS revenue that is largely uncorrelated with device volumes and carries improving margin profiles as the installed base scales. Management expects mid-single-digit annual growth from the RCS segment with SaaS margin expansion as the business transitions legacy on-premise customers to cloud-hosted delivery models. RCS revenue is strategically important beyond its direct financial contribution. MatrixCare penetration into residential care facilities positions ResMed at the point-of-care data node for the fastest-growing segment of US healthcare — home and community-based services for an ageing population. This creates a long-duration option on digital health services, predictive analytics, and care coordination revenue that is not reflected in current consensus models focused almost exclusively on the device business. While we do not ascribe speculative value to this optionality in our base case, the strategic positioning is real and differentiating. 4. **Capital allocation is compressing the share count and accelerating EPS growth** ResMed's $300–400 million annual share buyback programme is systematically reducing the diluted share count, driving EPS growth in excess of net income growth across our forecast period. Net income is forecast to grow from $1.0 billion in FY2024 to $1.9 billion in FY2028 — approximately 17% per annum compound — but EPS grows from $6.92 to $10.12 over the same period, a faster rate, because each earnings dollar is divided across a shrinking share base. This dynamic is often underweighted in consensus models that focus on revenue or EBIT growth in isolation. The balance sheet trajectory reinforces capital allocation capacity. Net cash is forecast to improve from $0.2 billion in FY2025 to $3.2 billion by FY2028, as free cash flow conversion above 30% of revenue comfortably funds both buybacks and the progressive dividend without leveraging the balance sheet. The Noctrix acquisition ($24 million annual revenue run rate, closing June 1 2026) demonstrates that management can pursue bolt-on M&A without compromising the buyback programme or dividend — the deal is financially immaterial to earnings but strategically significant in entering the restless legs syndrome market. A company generating $1.9 billion of free cash flow annually with $3.2 billion of net cash by FY2028 has substantial optionality for incremental buyback acceleration, special dividends, or transformative M&A — none of which is priced into the current multiple. 5. **Noctrix and RLS represent an early-stage but genuine market expansion catalyst** The June 2026 acquisition of Noctrix and its neuromuscular electrical stimulation device for restless legs syndrome adds a new therapeutic category to ResMed's portfolio. RLS affects approximately 17 million patients in the US alone and roughly 7% of adults globally — a patient population that is meaningfully underserved by pharmacological options, many of which carry augmentation risks that limit long-term utility. A non-pharmacological, device-based intervention delivered through ResMed's existing HME channel relationships has a credible path to commercial adoption if the clinical profile holds up in post-approval real-world use. At $24 million annual revenue and a closing date of June 2026, Noctrix contributes negligibly to FY2026 financials. The investment case does not depend on RLS becoming a major revenue driver in the near term. However, management's characterisation of expected growth and margins as superior to ResMed's baseline is notable — it suggests confidence in the clinical differentiation and channel receptivity. If the RLS opportunity develops toward even 5–10% of the sleep apnea business over a five-year horizon, it represents a material, consensus-beating upside scenario. We treat it as an unpriced call option. 6. **Valuation underprices the FCF profile and balance sheet inflection** At $213.81, ResMed trades at approximately 29x our FY2025 EPS estimate of $7.32 and 26x FY2026 EPS of $8.26. For a business delivering 9–11% revenue growth, 62–63% gross margins, 30%+ FCF conversion, a net cash balance sheet by FY2027, and a dominant market position in a structurally growing therapeutic category, this multiple reflects persistent GLP-1 discount rather than fundamental business quality. Comparably positioned medical device franchises with lower growth rates, weaker FCF conversion, or more leveraged balance sheets trade at equivalent or higher multiples. The discount is therefore not a reflection of quality — it is a reflection of a narrative that the earnings trajectory is now systematically refuting. As the GLP-1 overhang dissipates through continued volume evidence and the FCF and buyback story becomes the dominant investor framework, we expect the multiple to re-rate toward 30–32x on a forward basis, with EPS growth providing the additional return leg. The combination yields a FY2028 price target of $294, representing 37% upside from current levels.

Risks

1. **GLP-1 efficacy exceeds current clinical evidence** If subsequent large-scale trials demonstrate that GLP-1 agonists resolve sleep apnea in a materially higher proportion of patients than current data suggests — or if next-generation GLP-1/GIP combinations prove more efficacious in eliminating PAP dependency — the addressable device market contracts rather than expands. This is a low-probability but high-impact scenario that would require a fundamental revision of the thesis. The risk is not the current clinical evidence, which is manageable, but the possibility of superior outcomes from agents not yet in large-scale trials. 2. **CMS reimbursement compression and payer utilisation management** ResMed's revenue model is deeply embedded in US insurance reimbursement structures. CMS rate reductions, competitive bidding programme adjustments, or payer-level prior authorisation tightening (particularly through platforms like Synapse, flagged by management as an emerging utilisation management threat) could reduce effective device and mask pricing, squeeze HME distributor margins, and slow the resupply cycle. Management's own acknowledgement of Synapse as a potential channel disruptor deserves serious weight — if utilisation management platforms succeed in reducing mask resupply frequency, the recurring revenue base is directly impaired. This is the most proximate financial risk to the base case. 3. **Fabric mask pricing not generating HME profit in all payer combinations** Management acknowledged in recent channel feedback that fabric mask price points may not generate profit for traditional HME operators in all state and payer combinations. If HMEs deprioritise ResMed's premium fabric masks in favour of lower-cost alternatives — including Chinese-manufactured masks — volume growth in the highest-margin product category could disappoint. The mask and accessories recurring revenue thesis is partially predicated on premium mask adoption; if channel economics prevent that adoption, both revenue and margin assumptions require downward revision. 4. **Residential Care Software growth deceleration and competitive pressure** The Brightree and MatrixCare platforms face competition from specialist HME and senior care software vendors including Netsmart, PointClickCare, and smaller vertical SaaS entrants. If RCS growth decelerates below mid-single digits — due to competitive displacement, customer churn during cloud migration, or acquisition integration friction — the segment's contribution to overall revenue and margin expansion is reduced. More importantly, any impairment of the strategic positioning narrative around data and care coordination weakens the long-term optionality argument. 5. **Currency and geopolitical headwinds to gross margin** ResMed generates approximately 40% of revenue outside the United States. Management has explicitly flagged that FY2026 gross margin guidance of 62–63% is subject to currency movements, and that geopolitical uncertainty affecting fuel and component costs represents an acknowledged risk. A sustained US dollar strengthening cycle or supply chain disruption affecting Singapore manufacturing operations could compress gross margins below the guided range, with direct flow-through to EPS. Given the precision of margin guidance and its centrality to the investment case, even a 100 basis point gross margin miss would represent a meaningful earnings revision risk. 6. **Noctrix integration execution and RLS market development risk** The Noctrix acquisition introduces execution risk across product integration, HME channel education, and reimbursement pathway establishment for a new therapeutic category. RLS device therapy lacks the established reimbursement infrastructure that underpins ResMed's sleep apnea business, and HME channel adoption of a new device category requires clinical education investment and coding clarity that may take multiple years to develop. If the RLS market develops more slowly than management expects — or if the neuromuscular stimulation approach is superseded by pharmacological advances — the Noctrix investment thesis fails to generate the growth premium management has signalled. While the acquisition is financially immaterial in the near term, a visible execution stumble could damage management credibility on capital allocation and M&A strategy.

📈 Price Targets